SR-x Synthetic Cannabinoids Cannabinoid Research

SR-x Synthetic Cannabinoids Research Dashboard


Primary Studies


Related Studies


Total Studies

Clinical Studies


Clinical Meta-analyses


Double-blind human trials


Clinical human trials

Pre-Clinical Studies




Animal studies


Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 209 studies associated with SR-x Synthetic Cannabinoids.

Here is a small sampling of SR-x Synthetic Cannabinoids studies by title:

Components of the SR-x Synthetic Cannabinoids Research Dashboard

  • Top medical conditions associated with SR-x Synthetic Cannabinoids
  • Proven effects in clinical trials for SR-x Synthetic Cannabinoids
  • Receptors associated with SR-x Synthetic Cannabinoids
  • Individual study details for SR-x Synthetic Cannabinoids

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - SR-x Synthetic Cannabinoids

Description of SR-x Synthetic Cannabinoids

Rimbonant was first described marketed by Sanofi as a drug to combat obesity. Also known as SR-141716A the compound is an orally active selective antagonist at CB1 receptor sites. Rimonabant was sold as an effective weight loss drug in Europe until adverse effects (e.g., depression and suicidal tendencies) forced their makers to pull the drug from the market. It is extensively used to research the function of the endocannabinoid system (ECS).

Here we focus on SR-141716A.

Another members of of note is SR144528, a full antagonist at CB2 (M. Rinaldi-Carmona et al., 1998).

Other Names:

SR Family Synthetic Cannabinoids

Rimonabant, SR 141716, SR141716A, SR-141716A (plus other supplier-based synonyms)

IUPAC Name: 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide

Molecular Formula: C22H21Cl3N4O


SR-x Synthetic Cannabinoids Properties and Effects

Rimonabant (SR-141716) may: 

  • Induce gastrointestinal difficulties, anxiety, depression and/or suicidal ideations (E. Topol et al., 2022)

  • Prevent methamphetamine neurotoxicity (M. Khodamoradi et al., 2022)

  • Inhibit damage, inflammation, and fibrosis, and cancer-causing pathways in the liver (N. Helmrich et al., 2021)

  • Prevents myotube atrophy with potential relevance in the treatment of sarcopenia (O. Le Bacquer et al., 2021)

  • Suppress hepatitis B virus (HBV) propagation (A. Sato et al., 2020)

  • Rimonabant and THCV reduced weight gain partially modulated via GPR55 (E. Wargent et al., 2020)

  • Represent a novel treatment molecule for patients with Duchenne muscular dystrophy (Fabio A. Lannotti et al., 2018)

  • Rimonabant directly inhibits the Gαi/o protein (Alessandra Porcu et al., 2018)

  • Alters gut microbiota, reduce inflammation and diet-induced obesity (P. Mehrpouya-Bahrami et al., 2017)

  • Contribute to the underlying pathology of polycystic ovary syndrome (T. Sathyapalan et al., 2017)

  • Protect against stroke (Z. W. Reichenbach et al., 2016)

  • Reverses alterations in animal model of Fragile X Syndrome (M. Gomis-González et al., 2016)

  • Decrease symptoms of Parkinson's when co-adm. with L-DOPA (A. Gutiérrez-Valdez et al., 2013)

  • Protect against alcoholic-induced fibrosis (E. Patsenker et al., 2011)

  • Induce anxiety, depression and/or suicidal ideations (E. Topol et al., 2010; A. King 2010)

  • Protect against psychosis (D. Parolaro et al., 2010)

  • Decrease nicotine addiction (B. Le Foll et al., 2009; C. Cohen et al., 2005)

  • Be useful in treating patients with hemorrhagic shock (Li-chao Hou et al., 2009; M. Cainazzo et al., 2002; J. Wagner et al., 1997)

  • Reduce alcohol dependence (K. Yaragudri Vinod et al., 2008)

  • Inhibits human breast cancer cell growth (D. Sarnataro et al., 2006)

  • Inhibit lipopolysaccharide-induced inflammation (S. Raduner et al., 2006)

  • Reduce opioid dependence (M. Mas-Nieto et al. 2001; T. Rubino et al., 2000)

SR-x Synthetic Cannabinoids Receptor Binding

Endocannabinoid System (ECS) and SR-141716A: 

  • CB1 full antagonist with a of Ki ~2nM (M. Rinaldi-Carmona et al., 1994)

Endocannabinoidome (eCBome) and SR-141716A: 

  • Mu-opioid receptors antagonists (Kathryn A. Seely et al., 2012)

  • Modulator at GPR55 (E. Wargent et al., 2020)

  • Positive allosteric modulators of GABA(A) receptors (R. Baur et al., 2012) 

Ki legend:

  • Full/strong agonist Ki ~1-9nM

  • Moderate agonist Ki ~10-99nM

  • Weak agonist Ki ~100-999nM

  • Very weak agonist Ki ~1,000-up nM

(The reader is reminded that a smaller Ki is associated with the strongest effects.)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.